OPEN Foundation

Author name: OPEN Foundation

Lysergic Acid Diethylamide and mystical experiences

Abstract

The term psychedelic (“mind-manifesting”) was coined by British psychiatrist Humphry Osmond in 1956 to refer to a unique class of mind-altering chemicals with distinctive effects that set them apart from other drugs with hallucinogenic properties. Some psychedelics come from natural sources that have been traditionally featured in religious, ritual, and healing practices of indigenous cultures of the Americas (Anderson, 1980; Hofmann, 1983; Salak, 2007; Smith, 2000); such drugs include mescaline (from peyote and San Pedro cacti), psilocybin and psilocin (from Psilocybe mushrooms), and dimethyltryptamine or DMT (from the leaves of Psychotria viridis). Many other psychedelics have partly or wholly synthetic origins. The most potent psychedelic agent yet discovered is the semisynthetic ergot derivative lysergic acid diethylamide (LSD), which has distinctive effects at the microscopic dose of 25 μg; a typical psychedelic dose ranges from 50 to 200 μg. There are also a number of purely synthetic psychedelics, many of which are chemically related to both amphetamine and mescaline (Shulgin & Shulgin, 1991). One of the most potent of these is dimethoxymethylamphetamine, or DOM, which was known as “STP” when introduced to the hippie subculture of San Francisco in the late 1960s. More familiar today is methylenedioxymethamphetamine (MDMA, ecstasy), which has only mild or partial psychedelic effects as opposed to full psychedelics such as LSD, psilocybin, and mescaline; MDMA is thus sometimes described as an “entactogen,” meaning “touch within” (Bravo, 2001; Smith, 2000), as opposed to full psychedelics or “entheogens,” meaning “God within.” A newer, extremely potent synthetic psychedelic, 2-(4-iodo-2,5-dimethoxyphenyl)-N-[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][(2-methoxyphenyl)methyl] ethanamine (2CI-NBOMe, or “N-Bomb”), was invented in 2003 and is useful as a laboratory tool to map brain serotonin receptors (Ettrup et al., 2010). The threshold dose is several hundred micrograms, making this psychedelic second in potency only to LSD. Media reports indicate that 2CI-NBOMe has been sold to drug users on pieces of blotter paper, like LSD, and often misrepresented as the latter drug. Unfortunately 2CI-NBOMe has a much lower therapeutic index than LSD, hence several highly publicized deaths appear to have been caused by this drug (e.g., Hastings, 2013; Poklis et al., 2014) and, in some cases, possibly misattributed to LSD. Some of the deaths resulted from drug-induced seizures, whereas in other cases the individuals killed themselves accidentally or purposefully in a drug-induced psychotic or delirious state. By contrast, fatal reactions are extremely uncommon with the “classic” psychedelics LSD, psilocybin, and mescaline.

Lyvers, M. (2016). Lysergic Acid Diethylamide and mystical experiences. 10.1016/B978-0-12-800212-4.00078-9
Link to full text[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Lysergic Acid Diethylamide and mystical experiences Read More »

The Relationship between depression and use of ecstasy among adolescents in Taiwan

Abstract

Introduction: The aim of this cross-sectional study was to examine the relationship between depression and ecstasy use among adolescents in Taiwan by controlling for the effects of demographic characteristics and cannabis use.

Methods: A total of 10,262 adolescents aged 12-18 years completed research questionnaires that assessed their severity of depression, status of ecstasy use, and history of cannabis use. The participants were grouped into non-users, ex-users, and current users. Severity of depression among these three adolescent groups was compared using analysis of covariance (ANCOVA), considering the history of cannabis use and demographic characteristics as covariates.
Results: After controlling for history of cannabis use and age, the study found that current ecstasy users experienced more severe depressive symptoms than ex-users and non-users. The difference between ex-users and non-users was not significant.
Conclusion: This study found that current ecstasy users had more severe depressive symptoms than non-users and ex-users. Psychological health professionals must monitor depressive symptoms among adolescent ecstasy users and provide emotional regulation strategies and psychological intervention for those with significant depression.
Lee, K. H., Su, C. H., Hsiao, R. C., Yen, C. N., & Yen, C. F. (2016). The Relationship between depression and use of ecstasy among adolescents in Taiwan. Neuropsychiatry (London), 6(4), 124-127. 10.4172/Neuropsychiatry.1000130
Link to full text

The Relationship between depression and use of ecstasy among adolescents in Taiwan Read More »

The Entheogen Reformation

Abstract

In addition to promising leads for treating PTSD, addictions, depression, and death anxiety, 21st Century research at medical schools finds that with careful screening, insightful attention to the variables of set, setting, and dosage, psychedelic drug administration often facilitates significant spiritual experiences, meaningfulness, altruism, well-being, and similar prospiritual effects. This article calls for theologians, professors of religious studies, philosophy, sociology, and psychology to update their courses. It challenges leaders of religious organizations, ‘‘How can your institution incorporate these practices and benefit from them?’’

Roberts, T. B. (2016). THE ENTHEOGEN REFORMATION. Association for Transpersonal Psychology, 26.

Link to full text

The Entheogen Reformation Read More »

Abraham Maslow’s Interest in Psychedelic Research: A Tribute

In this brief tribute to Abraham Maslow, a founder of the Journal of Humanistic Psychology, his interests in psychedelic research are described by the author who served as his research assistant from 1966 to 1967.
Richards, W. A. (2016). Abraham Maslow’s Interest in Psychedelic Research: A Tribute. Journal of Humanistic Psychology, 0022167816670997.
Link to full text

Abraham Maslow’s Interest in Psychedelic Research: A Tribute Read More »

A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4 Methylendioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction

Abstract

BACKGROUND: We present a case of “ecstasy” ingestion revealing 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-dimethoxyamphetamine (3,4-DMA) and absence of cytochrome P450 (CYP)-2D6 MDMA metabolites.

CASE REPORT: A 19-year-old presented following a seizure. Initial vital signs were normal. Laboratories were normal with the exception of sodium 127 mEq/L and urine drugs of abuse screen positive for amphetamines. Twelve hours later, serum sodium was 114 mEq/L and a second seizure occurred. After receiving hypertonic saline (3%), the patient had improvement in mental status and admitted to taking “ecstasy” at a rave prior to her initial presentation. Liquid chromatography-time-of-flight mass spectrometry (LC-TOF/MS) of serum and urine revealed MDMA, 3,4-DMA, and the CYP-2B6 MDMA metabolites 3,4-methylendioxyamphetamine (MDA) and 4-hydroxy-3-methoxyamphetamine (HMA). The CYP2D6 metabolites of MDMA, 3,4-dihydromethamphetamine (HHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA), were detected at very low levels.

CONCLUSION: This case highlights the polypharmacy which may exist among users of psychoactive illicit substances and demonstrates that concurrent use of MDMA and 3,4-DMA may predispose patients to severe toxicity. Toxicologists and other healthcare providers should be aware of this potential toxicity.

Darracq, M. A., Thornton, S. L., Minns, A. B., & Gerona, R. R. (2016). A Case of 3, 4-Dimethoxyamphetamine (3, 4-DMA) and 3, 4 Methylendioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction. Journal of Psychoactive Drugs, 1-4. 10.1080/02791072.2016.1225324
Link to full text

A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4 Methylendioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction Read More »

Ayahuasca and Sumak Kawsay: Challenges to the Implementation of the Principle of “Buen Vivir,” Religious Freedom, and Cultural Heritage Protection

Abstract

The current environmental crisis can be approached, through many perspectives, as a civilizational crisis. Alternatives of human transcendence are identified in the Inca civilization to compensate for the malaise that characterizes the actual crisis. There is a multicultural dimension to the manifestations of Hoasca (or Ayahuasca) occurring in Amazonian countries. As employed by the Beneficent Spiritist Center União do Vegetal (UDV) in a religious context, it can contribute to the reconstruction of buen vivir (or in Quechua, sumak kawsay, meaning complete wellness), which served as the principle of the civilizations that preceded the colonization of the Americas by Europeans. Today, the State openly confronts the manifestation of the constitutional principles of buen vivir, religious freedom, and the protection of this cultural heritage. Here, the implications of the civilizational crisis and ways of overcoming it are approached from the standpoint of deep ecology, but the implications also reflect the doctrinal vision of the UDV to which the authors are affiliated.

Irigaray, C. T. J., Girard, P., Irigaray, M., & Silva, C. J. (2016). Ayahuasca and Sumak Kawsay: Challenges to the Implementation of the Principle of “Buen Vivir,” Religious Freedom, and Cultural Heritage Protection. Anthropology of Consciousness, 27(2), 204-225. 10.1111/anoc.12057
Link to full text

Ayahuasca and Sumak Kawsay: Challenges to the Implementation of the Principle of “Buen Vivir,” Religious Freedom, and Cultural Heritage Protection Read More »

Ayahuasca Treatment Center Safety for the Western Seeker

Abstract

Ayahuasca, an ancient Amazonian psychedelic tea traditionally used ceremonially among indigenous peoples, has recently become known as a possible treatment for a wide range of disorders. The awareness of this sacred medicine has grown exponentially over the past decade, attracting westerners from a wide variety of backgrounds, hoping to find treatment for a myriad of emotional and physical illnesses, as well as spiritual needs. In the wake of the commercialization and westernization of the use of ayahuasca, and the subsequent proliferation of ayahuasca treatment centers, this paper examines the benefits and possible risks of this form of therapy in an effort to create a safety protocol for Westerners in this context. The most practical approach to increasing safety for Westerners attending these Amazonian treatment centers is to educate the seeker prior to treatment and to provide access to specialized therapeutic aftercare services.

Ray, R. R., & Lassiter, K. S. (2016). Ayahuasca Treatment Center Safety for the Western Seeker. Anthropology of Consciousness, 27(2), 121-150. 10.1111/anoc.12060
Link to full text

Ayahuasca Treatment Center Safety for the Western Seeker Read More »

Psychological and neuropsychological assessment of regular hoasca users

Abstract

BACKGROUND: Hoasca (also called ayahuasca) is a N,N-dimethyltryptamine (DMT) – containing psychedelic brew originally used for magico-religious purposes by Amerindian populations of the Amazon Basin. Recently, Brazilian syncretic churches have helped spread the ritual use of hoasca to Western societies. The aim of this study was to evaluate substance use, and neuropsychological and psychological functioning of regular hoasca users within a religious setting.

METHODS: Assessment of socio-economic status, mood, personality traits, impulsiveness, drug use, quality of life, extrinsic and intrinsic religiosity, and neuropsychological function was performed on 30 volunteers from a U.S. branch of União do Vegetal (UDV), a Brazilian religion which uses hoasca ritually. We also assessed 27 non-hoasca-using control subjects matched by socio-demographic profile and church attendance. Mann-Whitney U, chi-squared and Fisher tests were used to analyze differences between groups. Spearman’s association and simple logistic regression tests were used to analyze the impact of frequency of hoasca use on dependent variables.

RESULTS: Relative to the control group, the UDV group demonstrated lower scores for depression (p=0.043, r=.27) and confusion (p=0.032, r=.29) as assessed by the Profile of Mood States (POMS); higher scores on the instrument Big Five Inventory (BFI) for the personality traits agreeableness (p=0.028, r=.29) and openness (p=0.037, r=.28); higher scores on the quality life domain role limitations due to physical health as determined by the instrument Medical Outcomes Study Short Form-36 – SF-36 (p=0.035, r=.28); less recent use of alcohol (p<0.001, φc=.57), greater past use of alcohol to intoxication (p=0.007, φc=.36) and past use of cannabis (p=0.001, φc=.45) as measured by the Addiction Severity Index (ASI), 5th edition; better score on a measure of memory vulnerability to proactive interference as measured by the California Verbal Learning Test – CVLT (p=0.040, r=.27). Lifetime use of hoasca was positively correlated with role limitations due to physical health (p=0.032, rs=.39) and negatively associated with lifetime heavy alcohol use (p=0.034, OR=0.979).

CONCLUSIONS: The findings indicate that religious use of hoasca does not adversely affect neuropsychological functioning and may have positive effects on substance abuse and mood.

Barbosa, P. C. R., Strassman, R. J., da Silveira, D. X., Areco, K., Hoy, R., Pommy, J., … & Bogenschutz, M. (2016). Psychological and neuropsychological assessment of regular hoasca users. Comprehensive Psychiatry, 71, 95-105. 0.1016/j.comppsych.2016.09.003

Link to full text

Psychological and neuropsychological assessment of regular hoasca users Read More »

Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review

Abstract

OBJECTIVE: The aim of this review was to determine the clinical and biological predictors of the ketamine response.

METHODS: A systematic research on PubMed and PsycINFO database was performed without limits on year of publication.

RESULTS: The main predictive factors of ketamine response, which were found in different studies, were (i) a family history of alcohol dependence, (ii) unipolar depressive disorder, and (iii) neurocognitive impairments, especially a slower processing speed. Many other predictive factors were identified, but not replicated, such as personal history of alcohol dependence, no antecedent of suicide attempt, anxiety symptoms. Some biological factors were also found such as markers of neural plasticity (slow wave activity, brain-derived neurotrophic factor Val66Met polymorphism, expression of Shank 3 protein), other neurologic factors (anterior cingulate activity, concentration of glutamine/glutamate), inflammatory factors (IL-6 concentration) or metabolic factors (concentration of B12 vitamin, D- and L-serine, alterations in the mitochondrial β-oxidation of fatty acids). This review had several limits: (i) patients had exclusively resistant major depressive episodes which represent a sub-type of depression and not all depression, (ii) response criteria were more frequently assessed than remission criteria, it was therefore difficult to conclude that these predictors were similar, and finally (iii) many studies used a very small number of patients.

CONCLUSIONS: In conclusion, this review found that some predictors of ketamine response, like basal activity of anterior cingulate or vitamin B12 concentration, were identical to other therapeutics used in major depressive episode. These factors could be more specific to the major depressive episode and not to the ketamine response. Others, like family history of alcohol dependence, body mass index, or D- and L-serine were different from the other therapeutics. Neurocognitive impairments like slower speed processing or alterations in attention tests were also predictive to a good response. These predictive factors could be more specific to ketamine. With these different predictor factors (clinical and biological), it could be interesting to develop clinical strategies to personalize ketamine’s administration.

Romeo, B., Choucha, W., Fossati, P., & Rotge, J. Y. (2016). [fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review]. L’Encephale. 10.1016/j.encep.2016.06.005
Link to full text

[/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Clinical and biological predictors of ketamine response in treatment-resistant major depression: Review Read More »

In-Person Psychedelic Community Picnic (Amsterdam) - July 29